Study of Escitalopram in the Treatment of Specific Phobia
Information source: Connor, Kathryn M., M.D.
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Phobic Disorders
Intervention: Escitalopram (Drug)
Phase: Phase 2/Phase 3
Status: Completed
Sponsored by: Connor, Kathryn M., M.D. Official(s) and/or principal investigator(s):
Kathryn M. Connor, M.D., Principal Investigator, Affiliation: Duke University
Summary
This pilot study is designed to assess the efficacy of escitalopram in the treatment of
specific phobia in adult outpatients.
Clinical Details
Official title: Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline
Secondary outcome: Response based on CGI-I category
Detailed description:
This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of
12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult
outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of
specific phobia.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adults 18-65 years of age
- DSM-IV criteria for specific phobia according to the MINI
- For women of childbearing potential, a negative serum pregnancy test at screening
- Written informed consent
Exclusion Criteria:
- Any current primary DSM-IV diagnosis other than specific phobia
- History of DSM-IV substance abuse or dependence within the last months
- Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder,
mental retardation, or other pervasive developmental disorder or cognitive disorder
due to a general medical condition
- Suicide risk or serious suicide attempt within the last year
- Clinically significant laboratory or EKG abnormality or unstable medical condition
- For women of childbearing potential, unwillingness to use an acceptable form of
contraception during the study
- Subjects needing concurrent use of psychotropic medications
Locations and Contacts
Dept of Psychiatry and Behvaioral Science, Duke Unviersity Medical Center, Durham, North Carolina 27710, United States
Additional Information
Starting date: September 2002
Ending date: September 2004
Last updated: July 19, 2005
|
